Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF | V.TLT.W

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by floatinketuckyon Jan 20, 2022 1:49pm

926 Views

Post# 34338381

Theralase Market potential $1.1 billion

243,308 new cases of bladder cancer each year in the U.S., Canada and Europe(1)

70%-168,000 are classified as NMIBC(2)
30%-50,400 become unresponsive to current standard of care treatment Bacillus Calmette-Gurin ( “BCGUnresponsive”) within 1 year(3)
Patients that fail BCG treatment are prescribed a radical cystectomy (5) (surgical removal of bladder and associated tissue)
Estimated: 80,470 new cases in US, and 11,838 new cases in Canada, 151,000 new cases of bladder cancer in Europe in 2019(1)

240,000(1) x 70%(2) x 30%(3) x ½ x $50,000(6) =

$1.1 billion

Patients in need, urgent demand for bladder cancer drug
Willingness to pay $50K - $150K(6)

Bladder cancer patients facing low quality of life after cystectomy From diagnosis to death, it will cost bladder cancer patients $89K-$200K(7) , as bladder cancer is the most expensive cancer to treat.

1) Key Statistics for Bladder Cancer – American Cancer Society (2018); Canadian Cancer Society (2019) and Bladder Cancer – European Cancer Patient Coalition
(2) https://www.uptodate.com/contents/bladder-cancer-treatment-non-muscle-invasive-superficial-cancer-beyond-the-basics#!
(3) The management of BCG failure in non-muscle-invasive bladder cancer: an update (2009)
(4) European Organization for Research and Treatment of Cancer (EORTC) - (Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-risk non-muscle-invasive bladder cancer-therapy options during intravesical BCG Shortage. Curr Urol Rep. 2016;17:68) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5769243/
(5) NCCN Guidelines Insights: Bladder Cancer, Version 5.2018, J Natl Compr Canc Netw 2018;16(9):1041–1053
(6) Willingness to pay per quality adjusted life year (QALY) for competitor drug, Pembrolizumab. Source: Cost-effectiveness of Pembrolizumab in Second-line Advanced Bladder Cancer, July 2018 (7) Sievert KD, Amend B, Nagele U, et al. Economic aspects of bladder cancer: what are the benefits and costs?. World J Urol. 2009;27(3):295–300. doi:10.1007/s00345-009-0395-z (8) 2025 estimated bladder cancer market (US, France, Germany, Italy, Spain, UK & Japan). Source: Global Data: Bladder cancer market size to more than triple to over $1.1 billion by 2025, April 2017

https://theralase.com/wp-content/uploads/2021/08/Corporate-PPT-09213.pdf

https://theralase.com/press-releases/

<< Previous

Bullboard Posts

Next >>

Silvercorp to expand into Ecuador with C$200M Adventus acquisition